Form 4: GoodRx Officer's Planned Stock Transactions

GoodRx Chief Accounting Officer Romin Nabiey reported the future vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Chief Accounting Officer Romin Nabiey reported transactions involving GoodRx Holdings, Inc. Class A Common Stock and Restricted Stock Units (RSUs).
• On February 8, 2026, 12,663 Restricted Stock Units are scheduled to vest, converting into Class A Common Stock.
• Concurrently, 5,215 shares of Class A Common Stock are scheduled to be disposed of at a price of $2.44 per share, likely for tax withholding purposes.
• Following these transactions, Nabiey's direct beneficial ownership of Class A Common Stock will be 172,923 shares.
• The transactions are made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-planned.
• Nabiey will retain 63,314 Restricted Stock Units after the reported vesting event.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine, pre-planned insider transaction related to executive compensation and tax obligations, which typically has no significant impact on company valuation or operational outlook.

Positives

• Chief Accounting Officer Romin Nabiey will increase direct beneficial ownership of Class A Common Stock by a net of 7,448 shares (12,663 acquired minus 5,215 disposed) following the reported transactions.
• The acquisition of 12,663 shares through RSU vesting demonstrates continued equity participation by a key executive.

Negatives

• The disposition of 5,215 shares of Class A Common Stock, valued at $2.44 per share, represents a reduction in direct ownership, even if for tax purposes.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market risks associated with holding equity.

Future Outlook

The remaining 63,314 Restricted Stock Units will vest in approximately equal quarterly installments over 15 quarters following the initial vesting date of August 8, 2023.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to the vesting of equity awards and subsequent tax-related sales, are routine disclosures for publicly traded companies. The indication that these transactions are pursuant to a Rule 10b5-1 plan suggests they are pre-scheduled and not based on new material non-public information.

Stakeholder Impact

• Shareholders: Minor impact as these are routine, pre-planned insider transactions that do not reflect a change in company strategy or performance.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of the remaining 63,314 Restricted Stock Units in approximately equal quarterly installments over 15 quarters.

Key Dates

Keywords

GoodRx, GDRX, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Executive Compensation, Stock Sale, 10b5-1 Plan